Publish date:

Thursday's Health Winners & Losers

Gene Logic rises on a pact with Lilly.

Gene Logic


entered an agreement with

Eli Lilly

(LLY) - Get Eli Lilly and Company (LLY) Report

to reposition some of the experimental treatments Lilly shelved or put on the back burner.

Under the agreement, Gene Logic will have the option to receive an exclusive license to any drug candidate that Lilly chooses not to pursue, and it would pay Lilly milestone and royalty payments. Gene Logic shares were up 10.6% to $1.67. Lilly's shares were up 1% to $57.61.

Shares of


(MRK) - Get Merck & Co., Inc. (MRK) Report

rose 1.2% to $42.68 after the company announced an agreement with

Ambrilia Biopharma

to develop drugs for cancer and infectious diseases. The agreement grants Merck exclusive licensing rights to Ambrilia's HIV and AIDS treatment candidates.

Generic drugmaker

Teva Pharmaceutical

(TEVA) - Get Teva Pharmaceutical Industries Limited Sponsored ADR Report

announced that the Food and Drug Administration gave tentative approval for the company's application to market its generic version of

Johnson & Johnson's

(JNJ) - Get Johnson & Johnson (JNJ) Report

Risperdal. Teva expects to receive final approval when the Janssen patent expires in December 2007. Shares were up 22 cents, or 0.6%, to $35.83.

Discovery Laboratories'


shares were boosted 16.4% to $2.48 following encouraging clinical trial results on its proposed lung disease drug Surfaxin. The drug was effective in preventing and treating bronchopulmonary dysplasia, a condition commonly occurring in premature infants with respiratory distress.



shares fell 4.6% to $3.53 after the company said its subsidiary Belcher Pharmaceuticals has finished the initial phase of its pharmaceutical manufacturing and R&D expansion plans.

Among other health care stocks moving were

TheStreet Recommends



, down 1.2% to $53.09,


(ICCC) - Get ImmuCell Corporation Report

, off 5.6% to $4.72,

Valera Pharmaceuticals

(VLRX) - Get Valeritas Holdings, Inc. Report

, 3.4% lower to $6.01, and

Advancis Pharmaceutical


, down 2.8% to $5.20.



was 1.2% higher to $22.36,



rose 7.6% to $28.50,


(ALKS) - Get Alkermes Plc Report

was gaining 2% to $15.85,

Rigel Pharmaceuticals

(RIGL) - Get Rigel Pharmaceuticals, Inc. Report

was 2.7% higher to $11.33, and

Integrated Biopharma

(INB) - Get Cohen & Steers Global Income Builder Inc Report

gained 10.4% to $9.95.